Exenatide-induced acute pancreatitis

Endocrine Practice

Volumn 16, Issue 1, 2010, Pages 80-83

  Ayoub, Walaa A ^a   Kumar, Ashok A ^a   Naguib, Hossam S ^a   Taylor, Harris C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLASE; CALCIUM CARBONATE; CHOLESTEROL; CREATININE; EXENDIN 4; FUROSEMIDE; GLIPIZIDE; HEMOGLOBIN A1C; INFUSION FLUID; INSULIN ASPART; INSULIN GLARGINE; LIPID; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; MULTIVITAMIN; PANTOPRAZOLE; SERTRALINE; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

ACUTE PANCREATITIS; ADULT; AMYLASE BLOOD LEVEL; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DISEASE DURATION; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; FOOD AND DRUG ADMINISTRATION; GALLBLADDER; GLYCEMIC CONTROL; HUMAN; INFORMATION PROCESSING; LIVER FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SYMPTOM; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PANCREATITIS; PEPTIDES; TOMOGRAPHY, X-RAY COMPUTED; VENOMS;

EID: 77649125869     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09104.CRR     Document Type: Article

References (17)

1. Dungan KM, Buse JB. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clin Diabetes. 2005;23:56-62.
2. Kolterman OG, Kim DD, Shen L, et al. Pharmoacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62:173-181.
3. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
4. US Food and Drug Administration. FDA alert: Information for healthcare professionals: exenatide (marketed as Byetta). Available at: http://www.fda.gov/Drugs/DrugSafety/ ostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm. Updated August 2008.
5. Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med. 2008;358:1969-1972.
6. Greenberger NJ, Toskes PP. Acute and chronic pancreatitis. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill Professional, 2008: 2005-2027.
7. Gumaste VV, Roditis N, Mehta D, Dave PB. Serum lipase levels in nonpancreatic abdominal pain versus acute pancreatitis. Am J Gastroenterol. 1993;88:2051-2055.
8. Lin XZ, Chen TW, Wang SS, et al. Pancreatic enzymes in uremic patients with or without dialysis. Clin Biochem. 1988;21:189-192.
9. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: A case report. Diabetes Care. 2006;29:471.
10. Naranjo CA, Busto U, Seller EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
11. Doherty MJ. Algorithms for assessing the probability of an adverse drug reaction. Respir Med. 2009;2:63-67.
12. Kaurich T. Drug-induced acute pancreatitis: Proc (Bayl Univ Med Cent). 2008;21:77-81.
13. Duboeuf T, De Widerspach-Thor A, Scotto B, Bacq Y. Acute glimepiride-induced pancreatitis [article in French]. Gastroenterol Clin Biol. 2004;28:409-410.
14. Roblin X, Abinader Y, Baziz A. Acute pancreatitis induced by gliclazide [article in French]. Gastroenterol Clin Biol. 1992;16:96.
15. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019-1027.
16. Yadav D. How accurate are ICD codes-9 for acute (AP) and chronic pancreatitis (CP)? A large VA hospital experience. Pancreas. 2006;33:508.
17. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.